| Autor: |
Dufrancais O, Verdys P, Plozza M, Métais A, Juzans M, Sanchez T, Bergert M, Halper J, Panebianco CJ, Mascarau R, Gence R, Arnaud G, Neji MB, Maridonneau-Parini I, Cabec VL, Boerckel JD, Pavlos NJ, Diz-Muñoz A, Lagarrigue F, Blin-Wakkach C, Carréno S, Poincloux R, Burkhardt JK, Raynaud-Messina B, Vérollet C |
| Jazyk: |
angličtina |
| Zdroj: |
BioRxiv : the preprint server for biology [bioRxiv] 2024 Aug 28. Date of Electronic Publication: 2024 Aug 28. |
| DOI: |
10.1101/2024.05.13.593799 |
| Abstrakt: |
Cell-cell fusion is an evolutionarily conserved process that is essential for many functions, including fertilisation and the formation of placenta, muscle and osteoclasts, multinucleated cells that are unique in their ability to resorb bone. The mechanisms of osteoclast multinucleation involve dynamic interactions between the actin cytoskeleton and the plasma membrane that are still poorly characterized. Here, we found that moesin, a cytoskeletal linker protein member of the Ezrin/Radixin/Moesin (ERM) protein family, is activated during osteoclast maturation and plays an instrumental role in both osteoclast fusion and function. In mouse and human osteoclast precursors, moesin inhibition favors their ability to fuse into multinucleated osteoclasts. Accordingly, we demonstrated that moesin depletion decreases membrane-to-cortex attachment and enhances the formation of tunneling nanotubes (TNTs), F-actin-based intercellular bridges that we reveal here to trigger cell-cell fusion. Moesin also controls HIV-1- and inflammation-induced cell fusion. In addition, moesin regulates the formation of the sealing zone, the adhesive structure determining osteoclast bone resorption area, and thus controls bone degradation, via a β3-integrin/RhoA/SLK pathway. Supporting our results, moesin - deficient mice present a reduced density of trabecular bones and increased osteoclast abundance and activity. These findings provide a better understanding of the regulation of cell-cell fusion and osteoclast biology, opening new opportunities to specifically target osteoclast activity in bone disease therapy. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
